Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 6/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27525284 | 0.81 | TP53 (0.39) | LMNATP53 | |
| SCHEMBL4982558 | 0.80 | SLC6A9 (0.43) | LMNATP53MEN1KMT2APOLB | |
| SCHEMBL9540969 | 0.79 | LMNA (0.46) | LMNATBXA2RTP53ENPP2MAPT | |
| SCHEMBL9539942 | 0.76 | HTR3E (0.47) | MAPTMEN1KMT2A | |
| SCHEMBL9635952 | 0.73 | LMNA (0.45) | LMNATBXA2RTP53ENPP2MAPT | |
| SCHEMBL4772386 | 0.73 | TP53 (0.51) | LMNATBXA2RTP53ENPP2MAPT | |
| SCHEMBL9635804 | 0.71 | LMNA (0.47) | LMNATBXA2RTP53ENPP2MAPT | |
| SCHEMBL4991751 | 0.69 | LMNA (0.45) | LMNATP53MAPTMEN1KMT2A | |
| SCHEMBL6881772 | 0.69 | DRD4 (0.48) | LMNATP53MAPTPOLB | |
| SCHEMBL27333233 | 0.69 | ENPP2 (0.38) | LMNATP53ENPP2GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7361657-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-7173054-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-7173034-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V (BE) (BE) | 2006-07-13 | — | — | US | disclosed |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-27 | — | — | US | disclosed |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. | 2005-10-20 | — | — | US | disclosed |
| US-6924287-B1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACATICA, N.V. (BE) | 2005-08-02 | — | — | US | disclosed |
| EP-1196408-B1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2004-09-15 | — | — | EP | disclosed |
| EP-1418175-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1196408-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000611-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154913-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | LMNA 706/4885TBXA2R 1729/4885TP53 3667/4885 |
| US-20050234047-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | LMNA 710/4885TBXA2R 1739/4885TP53 3678/4885 |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | LMNA 706/4885TBXA2R 1729/4885TP53 3667/4885 |
| US-20050239771-A1 | Respiratory syncytial virus replication inhibitors | CCNB3, CCNA1, CDK2 | LMNA 576/4885TBXA2R 1286/4885TP53 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.